THE SCOPE

Vol. 26, No. 4, Fall 2008

OUTSTANDING PROGRAM ON CANCER PLANNED FOR 2009 ANNUAL MEETING IN WASHINGTON, D.C.

The Marriott Wardman Park in Washington, D.C., will be the headquarters hotel of the Society of Toxicologic Pathology 28th Annual Symposium, "Cancer," June 21–25, 2009. Situated on sixteen acres in the Woodley Park area of Washington, D.C., the hotel is adjacent to a convenient Metro subway stop. The Marriott is within walking distance of the National Zoo and also close to the National Cathedral. Most popular sites of interest in the U.S. Capital are just a few Metro stops away. There are many dining options in or within two blocks of the recently renovated hotel.

Jerrold Ward, *DVM, PhD, DACVP,* Global VetPathology and **Kathleen Funk**, *DVM, PhD, DACVP,* EPL, Inc. are the Symposium Co-Chairs for the *2009 Symposium.* The 2009 STP Symposium will cover the broad topic of "Cancer" in animals and humans. Cancer is a major cause of death in humans throughout the world. Cancer involves all organ systems and has many etiologies including chemicals, viruses, and irradiation but also has many important modifying factors such as genetics and diet. Cancer is the endpoint of a multistage process which begins as focal hyperplastic lesions and progresses, often through benign neoplasia, to malignant neoplasia. Toxicologic pathologists are often involved in studies involving tumors as an endpoint, including basic cancer research, studies with genetically engineered mice, and toxicology and carcinogenicity assays for safety assessment of chemicals. This symposium will cover various aspects of cancer: human cancer, cancer biology, mechanisms of carcinogenesis, regulation of carcinogens, use of genetically engineered mice for carcinogenesis bioassays, and tumor

continued on page 3

WASHINGTON, D.C. ATTRACTIONS

You are encouraged to plan time before or after the meeting to explore this fascinating and beautiful city. Washington, D.C. offers a tremendous variety of sights and activities for attendees and families, and most are just a few subway stops from the Wardman Park hotel via Metro.

The National Zoo (no fee), which is the home of 2,000 animals of 400 different species, is less than a half mile from the hotel. Its best known residents are the giant pandas, Tian Tian and Mei Xiang, and their cub, Tai Shan.

The Smithsonian Institution (no fee)(**www.si.edu**) includes the Air and Space Museum, National Gallery of Art, National Portrait Gallery, Natural History Museum, American History Museum, American Indian Museum, African Art Museum, and 12 other museums. Visit **www.si.edu** for more details. Free highlights tours are offered at most Smithsonian museums.

The U.S. Capitol

The International Spy Museum (fee) is the only public museum in the United States solely dedicated to the tradecraft, history, and contemporary role of espionage. Artifacts of international espionage—from a 1777 letter by George Washington authorizing a New York spy network to a 1980s coat with a camera

continued on page 24

INSIDE

New Members.....2
STP News 2
STP Officer Candidates Announced .. 4–9
STP Education Fund 11–13
Member Spotlight 14
Career Paths Panel Discussion 16–20
Workshop in China 21
What's Your Diagnosis?.....21
The Wrinkled Section 22
Exhibit Opportunity at Annual Meeting. 22
Coalition Board News.....23
Apply for a Student Travel Award!.....25

NEW MEMBERS

Welcome! NEW MEMBERS

Chunyan Hu ..... National Chengdu Center for Safety Evaluation of Drugs/West China-Frontier PhaemaTech, Sichuan, China

Binod Jacob ..... Charles River Laboratories, Quebec, Canada

Jean-Francois Lafond..... Charles River Laboratories, Quebec, Canada

John Mackie..... IDEXX Laboratories, Queensland, Australia

Karamjeet Pandher ..... Pfizer, Connecticut, United States

Junko Shinozuka ..... Mitsubishi Tanabe Pharma Corporation, Michigan, United States

Sean Troth ..... Merck and Co., Inc., Pennsylvania, United States

Nicole Navratil ..... Marshall BioResources, New York, United States

Mary Lewis ..... Tufts Cummings School of Veterinary Medicine, Massachusetts, United States

New STP Members Fall 2009

For the Member-get-a-member campaign, the STP members cited as influential in the applicants' decisions to apply for new membership include: **Seong-Kwi Kang**, **Peter Mann**, and **Dan Morton**.

STP NEWS

- Michael Goedken was named co-chair of the Membership Committee and will succeed Sandra Eldridge as of July 2009.
- Kathleen Funk was commended by the Executive Committee for her excellent organization of the 2006–2009 annual meetings.
- LuAnn McKinney was named to succeed Brian Berridge as the next chair of the Continuing Education Committee. Her term begins in July 2009.
- U.S. government employees will be admitted free of charge to the Tuesday sessions at the 2009 meeting in Washington, D.C.
- STP dues were increased 10% in 2009 to support the INHAND initiative and rising costs.
- The STP Strategic Plan will be thoroughly reviewed in 2009.
- The theme of the 2010 STP meeting in Chicago will be Toxicologic Pathology of the Nervous System.

STP Newsletter **Society of Toxicologic Pathology**

Editor
Jim Crissman
989-631-2790 (MI)
Jwcrissman@gmail.com

Newsletter Committee
Alok Sharma
608-242-2712 x2856 (WI)
alok.sharma@covance.com

Amrith Nair
215-652-3657 (PA)
amrithraj_nair@merck.com

Bindhu Michael
215-652-3662 (PA)
bindhu_michael@merck.com

Frank Simutis
812-429-8113 (IN)
frank.simutis@bms.com

Brad Bolon
303-772-7664 (CO)
Brad@gempath.net

Randy White
812-429-8341 (IN)
randy.white@bms.com

Sue Pitsch, Executive Director
703-438–7508 (VA)

STP Headquarters
1821 Michael Faraday Drive, Suite 300
Reston, VA 20190-5348
www.toxpath.org
stp@toxpath.org

Send newsletter material to STP Headquarters at the address above, or by Fax to 703-438–3113.

The Society of Toxicologic Pathology Newsletter (ISSN #10761535) is published 4 times a year by the Society of Toxicologic Pathology, c/o AIM, 1821 Michael Faraday Dr., Suite 300, Reston, VA 20190-5348. Membership dues include $5.00 for the cost of publication. Send address changes to STP Newsletter, Society of Toxicologic Pathology, 1821 Michael Faraday Dr., Suite 300, Reston, VA 20190-5348.

Society of Toxicologic Pathology 28th Annual Meeting

continued from page 1

Pandas at the National Zoo

pathology. Continuing education courses on cancer drug development and other subjects with the Saturday NTP session, which will emphasize tumor pathology, will round out the Symposium on Cancer.

For all interested U.S. government employees, there will be a Tuesday-Only Session registration available at no charge. Registration is required by June 1, 2009. The Tuesday morning session is on Genetically Engineered Mice and the Tuesday afternoon session is on Background Disease in Animal Models of Toxicity: Relevance and Interpretation in Risk Assessment.

STP will once again have the NTP Symposium Chaired by **Susan Elmore**, *MS, DVM, DACVP,* NIEHS on Saturday, June 20, 2009 from 9:00 AM–4:30 PM.

The topic for 2009 is **Tumor Pathology and INHAND Nomenclature.** (Corresponding with the STP meeting theme of cancer.) The object of this symposium is to provide continuing education on interpreting pathology slides, to generate lively and productive conversation, and to have a good time! We will also include some examples and discussion of INHAND nomenclature as it pertains to neoplastic lesions. During each talk, the speakers will project a series of lesion images on one screen with a choice of diagnoses/answers on a separate screen. The members of the audience with wireless keypads will then vote anonymously and the voting results will be displayed on the screen. After each voting session, time is allowed for discussion. The images presented for voting and discussion may represent lesions that are rare and interesting, present a diagnostic challenge, are controversial or have nomenclature dilemmas. This is a free session for meeting attendees but due to space limitations registration is required.

The National Cathedral

The 2009 Continuing Education Courses, chaired by **Brian Berridge**, *DVM, PhD, DACVP,* GlaxoSmithKline will be four half-day concurrent courses on Sunday, June 21 (additional fee required). Sunday morning, "Cancer Therapeutics, Development Strategies in the Era of Targeted Therapies" and "Drug-induced Hematoxicity: What's New?" will be offered. Sunday afternoon, "Mechanism-based Adverse Events Associated with Chemotherapy" and "Drug Development for Pediatric Populations" will be offered.

For additional information on the CE courses please visit the STP Annual Meeting Web site at **www.toxpath.org**.

Statue of Abraham Lincoln at the Lincoln Memorial

ABSTRACT SUBMISSION DEADLINE IS MARCH 1, 2009

(This is one month earlier than last year.)

Visit: **www.toxpath.org**

INHAND NOMENCLATURE

Visit **www.toxpath.org/inhand.asp** to learn more about The INHAND Nomenclature project (International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice.)

This page also includes information on accessing the related go RENI Web site at **www.goreni.org**.

STP OFFICER CANDIDATES ANNOUNCED

The STP Executive Committee and Nominating Committee (**Gary Boorman**, Chair; **John Foster**; **Denise Bonous**; **Robert Sills**, and **Joel Leininger**) have selected six candidates for three 2009–2010 open STP officer positions. Candidates for President-elect are **Stuart Levin** and **Wanda M. Haschek-Hock** and candidates for the two open Councilor spots are **Douglas C. Wolf**, **Kevin McDorman**, **Armando R. Irizarry**, and **Susan A. Elmore.** All full and honorary members in good standing received the on-line ballot link *via* e-mail December 3. The deadline for voting is February 16, 2009. Members who prefer to submit their ballot by fax or mail will be able to download a pdf ballot. Election results will be announced in the Spring *Scope* newsletter and on the STP Web site. New officers will officially join the Executive Committee after the June annual meeting.

Biographies and Statement of Goals

PRESIDENT-ELECT

(Three-year term: Serves as Awards Committee Chairperson, Fundraising Committee Member. Serves as President after one year as President-elect; then one year as Past President.)

Stuart Levin, D.V.M., Ph.D.

Biosketch

Dr. Levin received his D.V.M. at the University of Missouri and Ph.D. at the University of Chicago. After a brief stint at the FDA in Washington, D.C., Abbott Laboratories made him an offer he couldn't refuse. His experience there provided a solid foundation for the practice of toxicologic pathology. During his tenure at Abbott, Stu had his first experience on project teams. After 6 years at Abbott he joined the Animal Health Diagnostic Laboratory at Michigan State University to pursue his goal of ACVP certification. Having accomplished this, he began work at Searle Pharmaceuticals in Skokie, IL. There he greatly expanded his pathology and drug development experience. He participated on many project teams, and was responsible for writing numerous summaries for regulatory agencies. Upon the demise of Searle, in 2003 he moved to TAP Pharmaceuticals where he became Director of Drug Safety. Recently, Takeda acquired TAP, and currently, Stu is Director of Pathology at Takeda Global R&D in Illinois.

In 1972 Dr. Levin joined the STP, then called the Society of Pharmacologic and Environmental Pathologists. His roles within the organization have included Membership Chair, member of the Executive Committee and Secretary-Treasurer. He currently serves on the Fundraising Committee. He was also chair of an *ad hoc* committee on the nomenclature of cell death, which was charged with making recommendations to Society members on appropriate terminology for cell death as observed in safety assessment studies (*Tox. Path.* 27:484–490, 1999).

Statement of Goals

Globalization is upon us. Toxicologic pathology is being practiced around the world. While most of our members reside in the U.S., many do not. And many of us, myself included, work for multinational corporations. Other societies of toxicologic pathology have formed around the world, but the STP remains the oldest, largest and arguably the most respected organization in this specialized field. I believe these facts are behind our greatest challenge in the coming years. The STP, and each of us individually, should realize that toxicologic pathologists around the world wish to emulate the accomplishments of our members. We need to find ways to encourage the development of their competencies. Putting our heads in the sand will not work. At the same time, economic realities will be a considerable challenge. It is likely that STP will have to work with smaller operating budgets. This will require even greater cooperation from our already dedicated members.

PRESIDENT-ELECT

(Three-year term: Serves as Awards Committee Chairperson, Fundraising Committee Member. Serves as President after one year as President-elect; then one year as Past President.)

Wanda M. Haschek-Hock, B.V.Sc., Ph.D.

Biosketch

Wanda earned a B.V.Sc. degree from the University of Sydney (1973) and a Ph.D. degree from Cornell University (1977). She is a Diplomate of the American College of Veterinary Pathologists (ACVP, Anatomic Pathology, 1977) and the American Board of Toxicology (ABT, 1980), and has a Certificate of Business Administration (2001). From Oak Ridge National Laboratory, she moved to the University of Illinois College of Veterinary Medicine in 1982 where she is currently Professor of Comparative Pathology and director of the Graduate Training Program in Toxicologic Pathology. She has served as Department Head (1995–2001) and as interim Associate Dean for Research and Director of the Veterinary Diagnostic Laboratory. Wanda has over 30 years of experience in toxicologic pathology with over 100 scientific peer-reviewed publications. She is senior editor of the *Handbook of Toxicologic Pathology* (1991, 2002) and *Fundamentals of Toxicologic Pathology* (1998). She has served on the Board of Directors of the ABT and CL Davis Foundation; as Associate Editor for *Toxicological Sciences,* President of the Society of Toxicology's Comparative and Veterinary Specialty Section, FDA's Veterinary Medicine Advisory Committee, and NAS's Committee on Submarine Contaminants. She has served on the Editorial Board of *Veterinary Pathology* and as ACVP Councilor (1997–2001).

Wanda has served the Society of Toxicologic Pathology as Councilor (1992–1996), Chair of the Executive Committee (1994–95), Secretary-Treasurer (2002–2005), Editorial Board (1992–1995), Board of Governors for the ACVP/STP Coalition for Veterinary Pathology Fellows (2004–2007), and Associate Editor for *Toxicologic Pathology* (2005–2010). She was awarded the Society of Toxicologic Pathology's Achievement Award in 2007.

Statement of Goals

As president, I will continue the momentum to achieve STP's vision of being an international leader through recruitment, advocacy, globalization, and collaboration. Together, we must continue to broaden STP's membership base and increase the supply of toxicologic pathologists; address issues of importance in the legislative and regulatory decision making areas; work with key allied organizations to increase effectiveness and impact; and serve our members, other scientists, and regulatory agencies by disseminating information through *Toxicologic Pathology*, annual meeting symposia, outreach training and the Web site. We need to continue and enhance our leadership in building international consensus on best practices and science based regulatory positions in support of product registration for the pharmaceutical, and chemical industries. Because of my commitment to education, I will serve as a bridge between the Society, academic training institutions, employers and regulatory agencies, to strengthen recruitment efforts and education in toxicologic pathology.

COUNCILOR

(Four-year term: Councilor serves as liaison to Committees on a two-year rotation.)

Douglas C. Wolf, D.V.M., Ph.D.

Biosketch

Dr. Wolf received his D.V.M in 1981 from the University of Missouri and, after 6 years in clinical practice, went to Purdue University where he completed his residency and Ph.D in Veterinary Pathology in 1991. Doug was a staff scientist from 1991–1997 at the Chemical Industry Institute of Toxicology (CIIT) where he studied chemical carcinogenesis. From 1997 until 2007 he was a principal investigator at the National Health and Environmental Effects Research Laboratory (NHEERL) of the U.S. EPA where he continued research in carcinogenesis and molecular pathology. Currently he is Assistant Laboratory Director for NHEERL. Doug has authored or coauthored over 110 journal articles, book chapters, and technical reports, and presented his work at numerous meetings. Doug is an adjunct faculty member at North Carolina State; UNC; and Virginia Tech. Doug has received awards for best paper in *Fundamental and Applied Toxicology*, Bronze medals from the U. S. EPA for work on risk assessment issues and a Gold Medal for the Perchlorate Risk Assessment team. Dr. Wolf sits on many working groups, committees, and scientific review organizations. Dr. Wolf has participated in many activities for the STP on the Symposium Committee, chair of the Continuing Education Committee and International Collaboration Task Force, and frequent session chair at STP symposia. He has also been very active in SOT as session chair and member of the Continuing Education Committee. Dr. Wolf is a Fellow of the International Academy of Toxicologic Pathologists and the Academy of Toxicological Sciences.

Statement of Goals

The STP has worked to become recognized as the premier professional organization of leaders in the science and practice of toxicologic pathology. I would work to enhance this image by advocating for STP among the end users of the data we produce. To fulfill our advocacy goal we, as a professional organization, need to increase our opportunities to educate and interact with regulatory agencies. We can increase our ability to accomplish this goal by collaborating with other organizations such as SOT to organize educational forums that provide us the ability to influence the regulatory, and potentially the legislative, agenda that ultimately impacts the value to which the information we produce is measured.

COUNCILOR

(Four-year term: Councilor serves as liaison to Committees on a two-year rotation.)

Kevin McDorman, D.V.M., Ph.D.

Biosketch

Kevin received a D.V.M. from the Virginia-Maryland Regional College of Veterinary Medicine (1995), residency training in veterinary pathology at North Carolina State University, and a Ph.D. in Toxicology from the University of North Carolina at Chapel Hill (2002). He was board certified in Anatomical Pathology by the American College of Veterinary Pathologists (ACVP) in 1999. Following post-doctoral training with the U.S. Environmental Protection Agency, Kevin spent nearly 4 years as a Veterinary Pathologist at Amgen and 2 years as a Scientist/Pathologist at Genentech, where he held various positions in both research and development sciences, was active in drug development team activities, and contributed to journal publications and regulatory submissions. He joined Charles River Preclinical Services, Nevada in 2008 as the Pathology Division Director. Kevin has served as a member of the STP Membership Committee (1999–2002), as a member and Chair of the Externship Subcommittee of the ACVP Recruitment Committee (2001–2006), as an ACVP Young Investigator Award judge (2002–2006), as a member of the STP Education Task Force (2002–2003), as a member-at-large, Committee Chair and 2008 Program Chair for the ACVP Education Committee (2003–2009), as founding Co-Chair of the STP Career Development and Recruitment Committee (now the Career Outreach Committee; 2004–2006), as Co-Chair of the STP-Sponsored Symposium at the ACT Annual Meeting (2004–2005), as a member of the STP Nominations Committee (2005–2006), as a member and ACVP Liaison for the STP Symposium Committee, and as a reviewer for *Toxicologic Pathology, Carcinogenesis, and Toxicology.*

Statement of Goals

The Society of Toxicologic Pathology is looked to as a global leader in scientific and regulatory policy, position, and practice. As we navigate through an increasingly complex business and regulatory community, STP leadership must remain forward-thinking and diligent while making prudent financial decisions. We have watched our Annual STP Symposium become a leading scientific program in toxicology and pathology and we are committed to continuing that pattern of success. We have also seen recruitment efforts grow into successful programs, awards, and outreach that have improved the numbers of students interested in careers in veterinary and toxicologic pathology. Increased communications and collaborations with allied professional organizations, international colleagues, and regulatory authorities have developed and should be ardently supported in this age of globalization. As a Councilor for the STP I would work hard to maintain and improve our organization's forward progress in education, recruitment, and globalization.

COUNCILOR

(Four-year term: Councilor serves as liaison to Committees on a two-year rotation.)

Armando R. Irizarry, D.V.M., Ph.D.

Biosketch

Armando earned his D.V.M. and Ph.D. in Veterinary Pathobiology at Purdue University in 1996 and 2002, respectively. His residency training was in Veterinary Clinical Pathology at Purdue University from 1996 to 1999. He is board-certified in Clinical Pathology (1999) and Anatomic Pathology (2003), and is currently a Research Advisor in the Division of Toxicology and Drug Disposition at Eli Lilly and Company. Armando has served the STP as an *ad hoc* reviewer for *Toxicologic Pathology* and member of the Bone Marrow Best Practices Working Group. He is a member of the editorial board of *Veterinary Clinical Pathology*, and *ad hoc* reviewer for *The Journal of Zoo and Wildlife Medicine*. He served as a member of the Education Committee of the ASVCP (2000–2004), proctor for the Clinical Pathology section of the ACVP certification examination in 2006, and member of the ACVP Role Delineation Working Group in 2007. He is an adjunct Associate Professor of Veterinary Clinical and Anatomic Pathology at Purdue University teaching undergraduate and graduate students, and is a contributor to Eli Lilly's Externship in Veterinary Pathology and Laboratory Animal Medicine. He is a member of Lilly's Liver and Gastrointestinal Safety Committee providing consultation and shared learning across teams and therapeutic areas. His professional interests include development of pharmaceuticals and biopharmaceuticals (particularly anti-cancer drugs), electron microscopy, drug-induced hepatotoxicity, education of veterinary professionals, and non-domestic animal pathology. He has authored or co-authored >35 peer-reviewed publications or book chapters, and given 35 presentations at workshops or at national/regional meetings.

Statement of Goals

As a Councilor I will be a strong champion of the Society's four main goals of recruitment, advocacy, globalization, and collaboration. I will utilize my experience in the education of veterinary professionals to support STP's efforts in the recruitment of students and non-veterinary professionals to the discipline of toxicologic pathology. It is of utmost importance for the STP to set the scientific standard of excellence in toxicologic pathology and continue to provide unbiased, scientifically-sound advice via activities such as "Best Practices" publications and outreach efforts. In the current difficult political and regulatory environment, our ability to influence regulatory agencies and the public will depend on providing objective and sound recommendations that reflect the expertise of our members and collaborations with toxicologic pathology organizations worldwide. Globalization is an increasingly important part of recruitment, regulatory toxicology, and organizational collaboration and, as a Councilor, I will be a strong advocate of these efforts.

COUNCILOR

(Four-year term. Councilor serves as liaison to Committees on a two-year rotation.)

Susan A. Elmore, M.S., D.V.M.

Biosketch

Susan earned an M.S. from NCSU in Genetics/Biotechnology (1987) and worked as a Research Associate in the Microbiology/Immunology Department for 10 years at UNC in Chapel Hill. She received her D.V.M. (2001) and completed a residency in veterinary anatomic pathology (2004) at NCSU College of Veterinary Medicine. Susan became board certified by the American College of Veterinary Pathologists in 2004. She is currently a staff scientist/pathologist for the National Toxicology Program (NTP) at NIEHS where she is primarily responsible for oversight and preparation of NTP technical reports for bioassay studies, Project Officer for pathology support contracts, and collaborative research with various intramural scientists. Prior to her current appointment at NIEHS, Susan worked as a toxicologic pathologist at Integrated Laboratory Systems in North Carolina and as a post-doctoral fellow at NIEHS. Susan has expertise in toxicologic pathology, molecular genetics and specializes in immunopathology, renal pathology and mouse embryology. She has over sixteen publications in the past 4 years, many are first authorships, and include peer-reviewed original findings, monographs, atlases, book chapters and reviews on contemporary and important issues to the field of toxicologic pathology. Susan has served the STP in various capacities including: SRPC Historical Control Data Working Group, Editorial Board Member of *Toxicologic Pathology* Journal, STP/ACVP Coalition Board of Governors, STP Symposium Committee, INHAND Immune System Working Group. Susan is also involved with the organization of the biannual RTP Rodent Pathology Course and organizes and chairs the popular NTP Symposium held each year in conjunction with the STP annual meeting.

Statement of Goals

Using my experience and perspective from being on STP committees and my employment I would be honored to represent each of you to continue the road of improving the STP for the profession and its members. The STP has a broad range of committees, subcommittees, task forces and working groups, each staffed by a very talented and dedicated group of member volunteers. These volunteers play an active leadership role and carry on the work of the STP. As Councilor I would represent and continue to support the STP's mission by serving as liaison for a variety of committees and helping to bridge the important and necessary work of the committees with the vision of the STP.

Society of Toxicologic Pathology

28th Annual Symposium Washington, DC

Marriott Wardman Park Hotel
June 21–25, 2009

STP 28th Annual Symposium: Cancer

Symposium Co-Chairs: **Jerrold Ward**, *DVM, PhD, DACVP,* Global VetPathology *and* **Kathleen Funk**, *DVM, PhD, DACVP,* EPL, Inc.

The 2009 STP Symposium will cover the broad topic of "Cancer" in animals and humans. Cancer is a major cause of death in humans throughout the world. Cancer involves all organ systems and has many etiologies including chemicals, viruses, and irradiation but also has many important modifying factors such as genetics and diet. Cancer is the endpoint of a multistage process which begins as focal hyperplastic lesions and progresses, often through benign neoplasia, to malignant neoplasia. Toxicologic pathologists are often involved in studies involving tumors as an endpoint, including basic cancer research, studies with genetically engineered mice, and toxicology and carcinogenicity assays for safety assessment of chemicals. This symposium will cover various aspects of cancer: human cancer, cancer biology, mechanisms of carcinogenesis, regulation of carcinogens, use of genetically engineered mice for carcinogenesis bioassays, and tumor pathology. Continuing education courses will include cancer therapeutics and development strategies as well as mechanism-based adverse events, drug-induced hematotoxicity, and drug development for pediatric populations. The Saturday NTP Symposium will emphasize tumor pathology and the INHAND international nomenclature program. Additionally, as a special opportunity for federal employees, the Society of Toxicologic Pathology is offering Tuesday as a "free" educational day to all interested U.S. government employees.

Human Cancer (Session 1)

Co-Chairs: **Jerrold Ward**, *DVM, PhD, DACVP,* Global VetPathology *and* **Samuel Cohen,** *MD, PhD,* University of Nebraska Medical Center

The first session will review various aspects of the etiology, diagnosis, pathology, treatment, and prevention of human cancers.

Cancer Biology (Session 2)

Co-Chairs: **Robert Sills**, *DVM, PhD, DACVP,* NIEHS *and* **Mark Simpson,** *DVM, PhD, DACVP*, National Cancer Institute

The session will focus on the use of mouse models and *in-vitro* systems to understand cellular and molecular mechanisms of human cancer and develop therapeutics strategies using state of the art imaging technologies.

Alternative Mouse Models for Carcinogenicity Assessment (Session 3)

Co-Chairs: **Dan Morton**, *DVM, PhD, DACVP*, Pfizer *and* **James Swenberg**, *DVM, PhD, DACVP,* University of North Carolina

The history, rationale for use and selection, design, and interpretation of p53+/-, rasH2, and other alternative mouse models used to support carcinogenicity assessment of compounds for registration will be discussed. Speakers from government and industry will review current and promising future models, the performance of the models in validation studies and studies submitted to support new pharmaceutical products, the use of positive control chemicals, and the need for historical control data. The session will conclude with a roundtable discussion of regulatory acceptance and other questions provided by the audience.

Background Disease in Animal Models of Toxicity: Relevance and Interpretation in Risk Assessment (Session 4)

Co-Chairs: **Diane Creasy**, *PhD, FRCPath,* Huntingdon Life Sciences *and* **Brian Berridge**, *DVM, PhD, DACVP,* GlaxoSmithKline

Preclinical animal models are generally considered to be a "clean" and consistent background of normal anatomy and physiology within which to evaluate the potential toxicity of putative therapeutic agents. But, spontaneous background findings both physiological, and pathological, manifest in these models and can be quite variable in character, incidence and severity within and between studies. Although an experienced toxicologic pathologist is accustomed to identifying and differentiating these changes from test article-related effects, the distinction is occasionally unclear due to random distribution across dose groups or overlap with those associated with test article treatment. This presentation will describe some of the more common non-proliferative and proliferative background changes in rodent and non-rodent preclinical animal models. The presentation will also outline approaches used by the pathologist to weight the evidence for or against attributing the morphologic or clinical pathologic change to administration of the test article. The aim is to provide the regulatory reviewer an understanding of these changes and their context in preclinical safety assessment.

Biological Factors that Impact Assessment of Human Relevance of Animal Neoplasia (Session 5)

Co-Chairs: **James Popp**, *DVM, PhD, DACVP,* Stratoxon *and* **James Klaunig**, *PhD,* University of Indiana

This session will examine several established mechanisms of carcinogenicity in rodents with application to human relevance. A variety of chemical and physical agents have the potential to produce adverse effects by causing heritable changes to the genome. Mutagenesis is not the only mechanism underlying heritable alterations to the genome. Understanding of the epigenetic mechanisms including, DNA methylation, may play a key role in a variety of chemical-induced toxicities, including carcinogenesis. Induction of DNA damage as well as modulation of epigenetic pathways involved in the cancer process have been shown following oxidative stress by chemical and physical agents. Since the same pathways modified in rodents are also the target of oxidative stress in humans, the relevance for this mechanism is important in assessing human risk and relevance. The mechanisms of photocarcinogenesis potentiation and induction by chemical and physical agents will be discussed. Of recent concern is the possible risk of nanomaterials in the induction of photocarcinogenesis. The utilization of transgenic and humanized rodent models in understanding human clinical response to anticancer drug treatment and genetic and environmental factors involved in cancer etiology, will also be discussed.

Global Regulatory Perspectives on Cancer Risk Assessment: ***Where Are We, Where Are We Heading?*** (Session 6)

Co-Chairs: **Doug Wolf,** *DVM, PhD, FIATP, ATS*, U.S. EPA *and* **Terry Peters**, *DVM,* U.S. FDA, CDER

Current approaches for using toxicologic pathology to assist in cancer risk assessment by global regulators include the use of Mode of Action and the Human Relevance Framework, when applicable. Attention will be paid to understanding cancer pathways and applying new technological approaches to future cancer risk assessment-based research.

Pathology of Rodent Neoplasia (Session 7)

Co-Chairs: **Robert Maronpot**, *DVM, MS, MPH, DACVP, DABT*, Maronpot Consulting, LLC *and* **Dave Malarkey**, *DVM, PhD, DACVP*, NIEHS

This session presents current issues that pathologists are faced with almost daily in efforts to achieve accurate diagnoses and valid interpretations of rodent models of cancer. Cancer progresses through a multistep process with accumulation of molecular alterations often leading to malignant behavior and death. Many factors, including those that are genetic, environmental, and/or inflammatory, can contribute to carcinogenesis. This session focuses on the diagnosis and morphological features of cancer development and differentiation with elaboration on possible mechanisms of cancer (chemically induced or mediated by inflammation) as well as interpreting neoplasia that occurs in the rodent with no human counterparts.

Register for the Meeting, Make Hotel Reservations, and Submit Abstracts at www.toxpath.org

Visit www.toxpath.org for session details and current meeting information.
Abstract Submission Deadline: March 1, 2009

EDUCATION FUND AND MEMBER COMPANIES SUPPORT SPEAKER OUTREACH

Over the past twelve months, STP has been well represented by member speakers who volunteered their time. This participation was arranged by the Continuing Education Committee and supported, in part, by the STP Education Fund. The Society has been able to participate thanks to members who have contributed to the fund this year and in the past. In addition, several companies generously provided travel support to their employees who were speakers at these functions.

On behalf of STP, thank you to all speakers, companies who supported travel, and STP members who contributed to the Education Fund.

Event/Date	Speaker/Topic	Source of Travel Support
SOT: Introduction to Pathology for Toxicologists and Study Directors, **Seattle**, WA, March 2008	**Sarah Hale**, DVM "Basic Concepts in Morphologic Pathology and the Roles of the Toxicological Pathologists"	EPL
SOT: Introduction to Pathology for Toxicologists and Study Directors, **Seattle**, WA, March 2008	**Paul Howroyd** "Important Induced Lesions, and Interpretation of Pathology Data in Non-Oncogenicity Studies"	MDS Pharma
SOT: Introduction to Pathology for Toxicologists and Study Directors, **Seattle**, WA, March 2008	**Ken Schafer**, DVM, PhD "Pathology Ednpoints in Routine Repeated Dose Toxicity Studies: A Review of Global Regulations"	Vet Path Services
SOT: Introduction to Pathology for Toxicologists and Study Directors, **Seattle**, WA, March 2008	**Dianne Creasy**, PhD, FRCPath "An Introduction to Pathology in Carcinogenicity Studies"	Huntingdon Life Science

Event/Date	Speaker/Topic	Source of Travel Support
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Mark T. Butt, DVM, PhD, DACVP** "Nervous System: "Structure and Function, Mechanisms/ Classification of Disease II" and "Case Examples"	Tox Path Specialists, LLC
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Dale G. Dunn, DVM, DACVP** "Basic Principles"	Covance
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Sarah L. Hale, DVM, DACVP** "Practical Applications," and "Risk Assessment and the NOAEL"	Experimental Pathology Laboratories, Inc.
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**James W. Crissman, DVM, PhD, DACVP** "Endocrine System: Normal Anatomy and Physiology"	Crissman Toxicologic Pathology, LLC
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Sundeep A. Chandra, DVM, PhD, DACVP** "Endocrine System: Adrenal and Thyroid: Spontaneous Lesions and Chemically Induced Alterations"	GlaxoSmithKline
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Kathleen A. Funk, DVM, PhD, DACVP** "Endocrine System: Pituitary, Parathyroid and Pancreatic Islets: Spontaneous and Chemically-Induced Alterations"	Experimental Pathology Laboratories, Inc.
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Kevin Keane, DVM, PhD, DACVP** "Nervous System: Mechanisms/Classification of Diesase I," "Testing for Neurotoxicity," and "Case Examples"	Schering-Plough
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**LuAnn McKinney, DVM, DACVP** "Endocrine System: Mystery Slides"	MedImmune, Inc.

continued on page 12

continued from page 11

ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**JoAnne M. Saye, PhD** "Endocrine System: What is Metabolic Symdrome X?"	AstraZeneca Pharmaceuticals
ACT/STP Pathology for Non-Pathologists Course, Falls Church, VA, May 2008	**Jeffrey C. Wolf, DVM, DACVP** "Endocrine System: Mystery Slides" and "Endocrine Disruption in Wildlife and Aquatic Animals"	Experimental Pathology Laboratories, Inc.

Event/Date	Speaker/Topic	Source of Travel Support
STP India Symposium on Hematopoietic-Immuno and Urinary Toxicologic Pathology, Hyderabad, India, October 2008	**Nancy Everds. DVM, DACVP** "Blood/ Bone Marrow"	Amgen
STP India Symposium on Hematopoietic-Immuno and Urinary Toxicologic Pathology Hyderabad, India, October 2008	**Shashi Ramaiah, DVM, PhD, DACVP, DABT** "Blood/Bone Marrow"	Pfizer, Inc.
STP India Symposium on Hematopoietic-Immuno and Urinary Toxicologic Pathology Hyderabad, India, October 2008	**Brian Short, DVM, PhD, DACVP** "Urinary System"	STP Education Fund
STP India Symposium on Hematopoietic-Immuno and Urinary Toxicologic Pathology Hyderabad, India, October 2008	**Paul Snyder, DVM, PhD, DACVP** "Immunotoxicology/Pathology"	STP Education Fund
STP India Symposium on Hematopoietic-Immuno and Urinary Toxicologic Pathology Hyderabad, India, October 2008	**Vishal Vaidya, PhD** "Urinary System Biomarkers"	STP Education Fund
STP India Symposium on Hematopoietic-Immuno and Urinary Toxicologic Pathology Hyderabad, India, October 2008	**Dana Walker, DVM, PhD, DACVP** "Immunotoxicology/Pathology"	Bristol-Myers Squibb

Event/Date	Speaker/Topic	Source of Travel Support
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Kevin Donnelly, DVM, PhD** "Toxicologic Pathology of the Cardiovascular System: Plenary and Workshop"	Covance
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Jeff Engelhardt, DVM, PhD, DACVP** "Toxicologic Pathology of the Urinary System: Plenary and Workshop"	Amgen
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Judy Yi Feng, BSc, MVM** "Toxicologic Pathology of the Urinary System: Plenary and Workshop"	Charles River
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Nicole Hamelin, DVM, MS, DACVP** "Toxicologic Pathology of the Urinary System: Plenary and Workshop"	Charles River

continued on page 13

continued from page 12

NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Helen Han Hsu, DVM, PhD, DACVP** "Training of Toxicologic Pathologists in the U.S."	Johnson and Johnson
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Xiantang Li, BVM, PhD, DACVP** "Common Background Changes in Tissues Associated with Animal Handling and Toxicity Study Processes" "Common Background Findings in Tissues of the Rodent, Dog and Primate" "Common Artifacts in Tissues Associated with Tissue Sampling and Processing—Quality Control"	Pfizer
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Vincent Meador, DVM, PhD, DACVP** **"**Fundamentals of Clinical Pathology in Toxicology" "Toxicologic Pathology of the Urinary System: Plenary and Workshop" "Toxicologic Pathology of the Cardiovascular system: Plenary and Workshop"	Amgen
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**William J. Reagan, DVM, PhD, DACVP** **"**Fundamentals of Clinical Pathology in Toxicology" "Toxicologic Pathology of the Cardiovascular System: Plenary and Workshop"	Pfizer
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Daniel G. Rudmann**, **DVM, PhD, DACVP** Co-chair, "Special Toxicologic Pathology Techniques and Emerging Technologies: Case Studies" **"Toxicologic Pathology: Important Patterns of Toxicity Observed in Industry"**	Eli Lilly and Company
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Monique Wells, DVM, MS, DACVP** "Best Practices in Anatomic Toxicologic Pathology" "Best Practices in Anatomic Toxicologic Pathology"	STP Education Fund
NCSED and STP China Toxicologic Pathology Workshop Beijing, China, October 2008	**Jerrold Ward, DVM, PhD, DACVP** "Rodent Carcinogenesis Bioassays"	Global VetPathology

The free 2008 annual meeting workshop "Effective Communication for the Toxicologic Pathologist," which was presented by the Career Outreach and Continuing Education Committees of STP was also supported (no travel support) by the Education Fund. Speakers were **A. Eric Schultze, DVM, PhD, DACVP** (Eli Lilly and Company), Co-chair; **Brian R. Berridge, DVM, PhD, DACVP**, Co-chair (GlaxoSmithKline); **Brad Bolon, DVM, MS, PhD, DACVP, DABT, FIATP** (GEMpath, Inc.); **John R. Foster, BSc, PhD, DipRCPath, FRCPath** (AstraZeneca); **Sabine Francke-Carroll,** (U.S. FDA); **John Vahle, DVM, PhD, DACVP** (Eli Lilly and company); **Jerrold Ward, DVM, PhD, DACVP** (Global VetPathology).

MEMBER SPOTLIGHT

THE MANY STRANDS OF CHARLOTTE'S WEB

By Bindhu Michael



Charlotte Keenan with husband Kevin Keenan (l.) and son Michael (r.)

Q. Where do you work and what are your main job responsibilities?

A. I am currently a Director in Regulatory and Investigative Pathology, Safety Assessment, GlaxoSmithKline and responsible for planning and conducting discovery and development projects and programs. My work is a stimulating mix of regulatory pathology studies, investigative pathology studies and project team responsibilities. I have the good fortune of managing and working with a talented group of anatomic pathologists in support of colleagues in discovery and full development.

Q. What are your primary pathology investigative/specialty interests?

A. Early in my career I had the opportunity to work on infectious disease, doing investigative work on hepatitis A in the owl monkey and visceral leishmaniasis in a dog model. The owl monkey colony had a plethora of spontaneous cardiovascular pathology which led me to delve into cardiac pathology (primarily cardiomyopathies). Later on while employed in a chemical company I had to work up a nasal cavity lesion and, thanks to the consultation and enthusiasm provided by colleague Kevin Morgan, developed my now long standing interest in the upper respiratory tract. Another area is the topic of historical control data as it relates to microscopic observations. This was fostered by my interactions with the International Life Sciences Institute (ILSI) and the efforts to establish a North American Control Animal Database. We can learn a lot from "history" if applied appropriately. I wonder if this had anything to do with the request for me to chair the Working Group on Historical Control Data for the SRPC???

Q. What aspect(s) in your current position (or career for that matter) you find most rewarding?

A. The opportunity to do the fascinating detective work of figuring out the changes in a tissue and what they mean —correlating structure and function—is very rewarding. Good morphologic description is the foundation and from there one brings in all the other clues from clinical signs, clinical pathology and the new "omics" to complete the story. Employment in the pharmaceutical industry has afforded me the chance to participate in multidisciplinary teams. I have worked with some great people and relish the challenge of bringing consensus to development issues.

Q. Where did you receive your veterinary and pathology training?

A. I attended the University of Pennsylvania School of Veterinary Medicine in Philadelphia, PA. Following graduation I was assigned to the Pathology Department at the Walter Reed Army Institute of Research in Washington D.C., where I had duties as a staff pathologist along with pathology residency training.

Q. What or who "sparked" your interest in pathology?

A. It started when I was assigned to spend my veterinary school freshman summer at the Walter Reed Army Institute of Research in Washington D.C. I had been accepted into the Army Veterinary Corps scholarship program and part of the commitment was to spend 45 days on active duty each summer while in veterinary school. I had actually requested Hawaii but for some reason the Army decided to send me to Washington D.C. Perhaps typical of government red tape my orders somehow never made it to the department I was assigned to—Pathology. I showed up on their doorstep with orders in hand and was presented to then LTC Paul Hildebrandt. Paul was cool "under fire" and quickly arranged for temporary accommodations while we got it all sorted out. It was a summer of firsts all around—my introduction to pathology and the predominantly male department's introduction to a woman vet student. I can still vividly remember sitting with Paul at the microscope reviewing tissues from a dog with distemper. Once he pointed out a few of the viral inclusions, the tissue just lit up. He was so animated when talking about disease and tissue responses and his enthusiasm was quite contagious! What I learned that summer laid a strong foundation for sophomore year pathology and there was no turning back—I was hooked. And the University of Pennsylvania had outstanding pathology faculty who continued to "fan the flame"—J.T. McGrath, Alan Kelly, David Dodd, Jim Rooney, Mike Goldschmidt among others. Following my graduation from veterinary school I had to complete a tour of duty and was thrilled to be assigned once more to Walter Reed. I continued my pathology education under the tutelage of Paul Hildebrandt, Chuck Montgomery, Tony Johnson, Mike Reardon, Bob Kovatch, and Jim Moe to name just a few. In addition, I benefited from interactions with colleagues at the Armed Forces Institute of Pathology and US Army Medical Research Institute for Infectious Diseases at Fort Detrick in Frederick, MD.

continued on page 15

continued from page 14

Q. Tells us about your family.

A. My husband Kevin Keenan, also a veterinary pathologist, currently working for Charles River and our son Michael, recently graduated from college and working as an athletic trainer.

Q. What pets do you have?

A. We lost our greyhound Frosting to old age last year. She was a "retired" racer rescued through the National Greyhound Adoption Program in Philadelphia. I can personally attest to the wonderful disposition these dogs have—they make great household pets. Kevin is raising homing pigeons but that is another story altogether.

Q. What are your hobbies/interests?

A. I was a "soccer mom" before the phrase became main stream. Our son asked if he could play soccer at the age of 7 and I quickly got caught up in rounds of practice, games, and travel teams. His love of sports continued *via* basketball and lacrosse and from grade school through to high school. Initially to have a means of communicating with our son, I started reading the sports page and helped out in the local athletic organizations and school teams that he participated in. Over time this evolved into more extensive involvement as a volunteer in the local community athletic association; at one point I was coordinator for an intramural basketball program that served over 600 children. The start of the season was always hectic (volunteer meetings, registrations, database entry, recruiting coaches, uniforms, etc, etc) but very rewarding to see the excited faces of 7 and 8 year olds as they made their first basket and the appreciation from parents knowing their children had a healthy activity to participate in. I have since "retired" from this activity and I am pondering my next creative outlet. Following sports is still on my list so when my son calls to say hello, I can converse about the latest stats on his favorite teams….

Q. Your formula to "doing it all" and balancing the juggling act of being a "soccer mom" and handling the home responsibilities, community volunteer, and a successful career woman?

A. If I had a magic formula I would certainly bottle and patent it! Knowing yourself (how much you can reasonably handle) and pacing yourself are key elements to making sure you don't burn out. It took me a while but I did learn to say "no" when the activity was outside of my interests or would take more time than I could reasonably budget for. It also helps to recognize that all social interactions (like work interactions) involve a degree of "politics" and dealing with "personalities". When you do get engaged and have the opportunity to make a contribution, it gives you a positive energy that benefits not only yourself but your family.

Q. Any early ideas on your next "creative outlet"?

A. Recent re-connections with family cousins have sparked my interest in researching out my family tree. I may take some courses on genealogy.

Q. What do you see yourself doing when you retire?

A. Some type of volunteer work. I like projects where there is visible evidence of completion, so maybe something like Habitat for Humanity (if my joints and muscles are up for it).

Q. Any advice or tips to other pathologists?

A. I would encourage all pathologists to get involved beyond their immediate work and home responsibilities. Getting engaged and volunteering in whatever area piques your interest or utilizes your skill sets is worth the challenge, energy and effort—the return on that investment is very satisfying!

Q. Just for fun: Is there something you would like to mention to the member community that they would be surprised to know about you.

A. I am an avid fan of murder mysteries (Patricia Cornwell is a favorite) and relish action/adventure and science fiction/fantasy movies (Lord of the Rings is my all time favorite).

BEHIND THE SCENES

Stephanie Dickinson is Toxicologic Pathology's *Managing & Production Editor*

Stephanie Dickinson is *Toxicologic Pathology's* Managing & Production Editor. Stephanie began working with STP in 1994 serving as Executive Director prior to assuming responsibilities for the journal in 2001. Stephanie is responsible for the overall operations of the editorial office facilitating communications between the editors, authors, and reviewers. She assists the Editor-in-Chief in developing and implementing journal initiatives and serves as the liaison between the Society and the publisher in areas relating to online editorial content, special supplements, production, and advertising. She also served as a consultant for the Society in the search and selection of a new journal publisher.

Stephanie graduated from LaSalle University with a BA in Communications. She earned her CAE (Certified Association Management) certification from American Society of Association Executives (ASAE) and is active in her local chapter of ASAE having served in various positions including Chapter President.

CAREER PATHS TAKEN ARE NOT ALWAYS STRAIGHT: A PANEL DISCUSSION

The Career Outreach Committee Career Development Lunchtime Series, STP 2008 Annual Meeting, San Francisco an informational panel discussion with 4 STP members who have taken different career paths to share the experiences gained as a result.

Participants:

Participant to Contact	Current Position	Career Path Represented	Contact Information
Peter Mann (Pres. Elect)	CRO	Academia ➔ Pharma ➔ CRO with Pharma embedding	206-284-1900 pmann@epl-inc.com
Jack Harkema	Academia	Government/Private Foundation ➔ Academia	517-353-8627 harkemaj@msu.edu
Bob Dunstan	Biotech	Academia ➔ Pharma/merger survivor ➔ Biotech	616-914-1205 Bob.dunstan@biogenidec.com
Curtis Colleton	Pharma	Military ➔ Private Practice ➔ Business Owner➔ CRO ➔ Pharma	812-429-8148 curtis.colleton@bms.com

The CD Subcommittee sponsored a Career Development Lunchtime Series on Monday June 23rd, 2008 in San Francisco entitled, "Career Paths Taken Are Not Always Straight: A Panel Discussion". This informational lunch-time session related the various career paths taken, decisions made, and experiences gained as a result, as told by four STP Members who have taken different career paths.

The panelists included: **Peter Mann** (STP President-elect), EPL, Inc., representing a career path from Academia to Pharma to CRO with embedding in Pharma; **Bob Dunstan**, Biogen Idec, Inc., representing a career path from Academia to Pharmaceutical (including down-sizing) to Biotech; **Curtis Colleton**, Bristol-Myers Squibb Co., representing a career path from Military to Private Practice/business owner to CRO to Pharma; **Jack Harkema**, Michigan State University, representing a career path from Government/private foundation to Academia; **Donna Dambach** (Host of CD Session), Genentech, Inc., representing a career path from Academia to Pharma to Biotech. These panelists were also asked to answer a series of career profile questions, which will be published in upcoming Scope issues, the Student Newsletter, and on the STP Web site's Career Development Area.

This session was very well-received with 52 participants who ranged from students to seasoned pathologists. The audience participation was phenomenal with numerous questions and additional comments and career path examples shared by participants in the audience. The session continued a half-hour beyond the 1 hour allotted time. The feedback received from the panelists was very positive as was feedback from the audience participants. Suggestions for future sessions included continued diversity, in particular more female representatives, and international pathologists. Based on the success of this panel approach, it will be repeated in 2009 and the Career Outreach Committee (COC) Career Development Subcommittee will select the proposed panelists. Finally, the STP membership community has rich experiences that are extremely valuable to us all and we deeply appreciate those colleagues who take the time to share those experiences. The COC Career Development subcommittee welcomes the contribution of any STP member who would like to share their experiences to contact us and be involved in our next or future sessions! Please feel free to contact Donna Dambach or any member of the COC.

Career Development Lunchtime Series—Peter Mann, DVM, DACVP

a. What is your current position? I am currently the Manager of EPL Northwest. In this position I oversee out bustling Office of One. I spend approximately 35% of my time in my home office (reading slides in my pajamas according to many), 25% of my time supervising necropsies and reading studies at a local CRO, and 40% of my time traveling to, conducting and returning from peer reviews or primary reads for clients. I have several small clients for whom I am the Pathologist of Record – one of them currently occupies a significant portion of my home office time.

b. What was your career path? My undergraduate degree was in English literature. After a year spent as a full-time substitute teacher in public schools, and several years as a part-time musician, I decided to go back to school to see if I could become a veterinarian. I got in and gravitated toward lab animal pathology while at the University of Missouri. I went directly from Missouri to a pathology residency at the National Zoo in Washington, D.C. After three years at the Zoo, I went to the University of Pennsylvania, where I passed my Boards, and spent most of my time with recently deceased racehorses at New Bolton Center. After three years, I went into industry, taking a position with ICI Americas, which has since morphed into Astra Zeneca. In 1989, ICI closed down their R&D site in the U.S. I then joined EPL, where I have remained for the last 19 years. I spent the first year with EPL in Harrogate, a small town in North Yorkshire in the United Kingdom. I then returned to the U.S., and spent 10 years with EPL in RTP, North Carolina, first as a staff pathologist, then a Lab Director, and then as a Director of Special Projects (a title that usually means your management doesn't know what to do with you!) After 10 years in North Carolina, I took a position as an Embedded Pathologist at DuPont Pharma in Wilmington, Delaware. I was an in-house contractor, with Dupont as my only client—they controlled my calendar, and I read in-house studies so that their staff pathologists were able to spend their days going to meetings and working on project teams. When BMS bought DuPont Pharma, they closed the site, and I established EPL NorthEast in our home in Maryland. I had a staff of one, whose main job was to bark at the FedEx driver. The work mix at NorthEast was similar

continued on page 17

continued from page 16

to my current mix. In 2007, my beloved, Dr. Everds, took a position at Amgen in Seattle, and I changed EPL NorthEast to NorthWest (fairly simple—stick in a W, shrink the e and loose the a.) We have been in Seattle for 1½ years.

c. What was the impetus behind your career changes? Academia: I was a junior staff member at Penn. It was very difficult to find any research funds. I had one small project where I had implanted a transmissible nasal tumor into sheep, and then put them out to pasture for a year to see if the tumor would grow in the recipients. One morning I received a phone call from the school, "Dr. Mann, I'm sorry but some dogs broke into the farm and ate your research project." At that point I decided to move on to industry.

Industry: After 4 years, ICI closed down their US R&D site. I had wanted to spend some time in the United Kingdom, so when EPL had an opportunity in England, I went for it. After 1 year, the amount of work available in the UK decreased, so I returned to the States, to EPL in North Carolina. After 10 years in North Carolina, I had the opportunity to be embedded at DuPont Pharma in Delaware. Since Dr. Everds was working there, that was a no-brainer—it saved a lot of gas and time we were spending for weekend visits. After BMS bought DuPont Pharma, they closed the Delaware site, and I established EPL NorthEast. When Nancy decided to move to Amgen, I was able to easily reconfigure as EPL NorthWest.

d. What did you take away from each position that was positive or negative?

Univ. of PA:

Pro: Teaching, working with Vet Students, training residents, ability to do independent research

Con: Low salaries, lack of funding for research, academic politics, long hours, and weekends

ICI:

Pro: learning to read safety studies, learning about drug development, good salary, and regular hours

Con: Attending endless meetings, lack of loyalty of big companies

EPL:

Pro: Realizing I could still read studies. Developing my skill set as a slide reader, peer review pathologist. Opportunity to try management (Didn't like it). Running a small office (one person). Being a major player in a small company. Developing my own client base, and determining my own schedule.

Con: Slightly lower salary than pharma. Benefits not quite as good.

e. What advice do you have in making career path decisions? Life is too short to be miserable. There are many possibilities as pathologists and no choice has to be permanent. Go for it.

f. What were your biggest misconceptions or ah-ha moments during career changes? When I left academia, I was assured by my colleagues that I was going over to the dark side. Not true. I have enjoyed almost every moment of my career. I used to be jealous of my colleagues who stayed in academia—they could do any research they desired. Then I realized that they had very small budgets and spent most of their time trying to find funding. When I got to EPL, I realized that I still knew how to read studies, even though I had spent much of the last four years in meetings. When BMS closed down DuPont Pharma, I realized (once again) that big companies are not very secure places to work.

What I realize every day is that I love pathology. I enjoy reading slides and interacting with other scientists in the drug discovery process. I learn something new with every project and at least two or three times a year I see something that I have never seen before—something that makes me stop and go, **"Wow, is that cool or what?"** What a great job.

Career Development Lunchtime Series—Donna M. Dambach, VMD, PhD, DACVP

Question A: What is your current Position?

Associate Director, Investigative Safety Assessment, Genentech, Inc.

Question B: What is your career path?

After completing my residency, I took a 3-year position as a Lecturer & Diagnostic Pathologist (Pathobiology Department, School of Veterinary Medicine, University of Pennsylvania). I then moved to the Pharmaceutical Industry (Bristol-Myers Squibb Company) as a pathologist and also completed my PhD while working and stayed at Bristol for almost 10 years before moving to my current position at a large Biotechnology Company (Genentech, Inc.) at the end of 2006.

Question C: What was the impetus behind your career changes?

I loved academia and would have made my career in that field, but during the late 1990's two things were making it difficult for me to stay: (a) I had chosen not to complete a PhD, and (b) there were few positions for clinician educators. I had no desire to have a primary career as an NIH-funded researcher and although I had extensive teaching, clinical research, and diagnostic experience, my lack of PhD did not make me competitive for other academic positions. Through networking, I was given the opportunity to take a Post-Doctoral Position in the Department of Experimental Pathology, Bristol-Myers Squibb while earning my PhD (funded entirely through BMS). I remained at BMS for nearly 10 years because the position (toxicologist and pathologist in Discovery Toxicology and Regulatory Toxicology) was intellectually stimulating and challenging and it was continually expanding and transforming, thus giving me great career development. I was quite happy with my career progression at BMS but decided to move on to large biotechnology for my career development as a leader (my task was to establish and build a new group) and for personal reasons (to explore the west coast).

Question D: What did you take away from each position that was positive or negative?

Many, many things, but I will keep it succinct. Feel free to call, e-mail or chat with me at a meeting for details! While in academia I learned that I loved to teach and help students to get excited about thinking and problem solving as it related to veterinary medicine. I still feel that an academic position is one of the highest honors someone can have because they are empowering generations of new veterinarians and veterinary pathologists. The "negative" that I experienced occurred when I decided to go to industry and the faculty summarily disrespected that decision. This notion that industry is the "dark

continued on page 18

Continued from page 17

side" is a fallacy and even more so when your mentors and colleagues in academia have no experience or understanding of the scope of activities and opportunities in industry. I think this is an extreme disservice to our students and residents.

From my > 10 years of experience in industry I have learned that good science can be accomplished in industry, especially in the research or discovery toxicology setting and now more than ever in the regulatory setting. I also learned many life skills including: how to interact in a collaborative and collegial manner on large teams and to influence others, how to manage and resolve conflict. Finally I have learned how by combining good science with good business practice leads to valuable outcomes that can be measured. On the negative side, although I have been very successful, there is still discrimination between men and women in big pharma. It is often very subtle (e.g. opportunities given and pay differences) and sometimes very overt (e.g. at top level meetings <20% of attendees are women or a woman's comments are ignored yet a male colleague who follows with the same comment is acknowledged), but for women to be successful they need to learn how to function most appropriately in this environment to get the most out of their career progression. Three things I highly recommend to this end: (a) take leadership courses in general but also those that specifically cater to women—They have their own "issues" because of the way they move in the world, (b) join a professional women's mentoring network and use it!!, and (c) read literature regarding how to move in the business world, such as "Her Place at the Table", or "Nice Girls Don't Get the Corner Office".

Question E: What advice do you have in making career path decisions?

Be open-minded and intentional and constantly expose yourself to new ideas. Few people have an arrow-straight career path. You will actually experience more and learn more because you are confronted with many choices, none of which are wrong. Also, be aware that you have time and that if a choice is presented to you that you feel you are not "ready to take", do not totally dismiss that potential opportunity as a future opportunity and stay in touch with the person who offered it to you….they may serve you well in the future in many ways but mostly as a mentor or networker. Talk to people and listen to their stories and network. I have never met someone who did not want to tell me their story/experience or to help me if I asked for help—people will bend over backward to help you. Do not be afraid to ask questions of any kind—especially for clarification, and to ask for help. Finally, every position will have good and bad points. Pay attention to both and be honest in asking yourself why something was bad or good and learn from it.

Question F: What were your biggest misconceptions or ah-ha moments during career changes?

My biggest misconception was how wonderful change is as a career development tool. I openly embrace and now look forward to change. Imagine if nothing changed! How stagnant would your career be…bottom line is to figure out how you can benefit from change.

My ah-ha moment occurred when I went on a job interview on a whim because the person who requested it was my friend. In that situation, I was totally relaxed because I had nothing at stake and I was able to candidly ask questions about things that I felt would be important for my career. I also realized how much I learned about what other people do and differences in job opportunities that I would not have been aware of if I had not explored different opportunities. The result was that I began to have a clearer picture of what I wanted from my career and it helped me to map out and implement my career path. So, I think it is a great idea to keep exploring other opportunities just so that you can help clarify what you want in your career….but understand that as you take on new roles or responsibilities those experiences will also help to continue to form what you want to do. Just be open to what is working for you and what is not and go from there.

Career Development Lunchtime Series—Robert W. Dunstan, DVM, MS, DACVP

a. What is your current position? Distinguished Investigator, Biogen Idec, Cambridge, Massachusetts

b. What was your career path?

Michigan State University (Resident to Full Professor)

1979—Residency in Anatomic and Clinical Pathology

1982—MS in Pathology (Designing a serologic test for a lysosomal storage disease)—DACVP—Appointed as an Assistant Professor, Department of Pathology (function primarily as a diagnostic pathologist/teacher)

1983—Began specialization in surgical pathology/dermatopathology

1988—Sabbatical at Jackson Laboratory to learn genetics research, decided to pursue research in dermatopathology

1991—Appointed full professor

1997—First substantive extramural funding obtained ($200K, the Iams Company)

Texas A&M University (Full Professor)

1998—*Pfizer Global Research and Development, Ann Arbor, MI (Research Associate to Associate Research* (Scientist) Appointed full professor, ran largest academic dermatopathology service and Comparative Dermatopathology Laboratory (specializing in hair follicle research and molecular bases of heritable cornification defects of animals)

2002—Hired to perform safety studies for Anaderm, a newly formed dermatology therapeutic area

2003—Reassigned to the Investigative Pathology Laboratory

2004—Head of Investigative Pathology, (specialized in dermatology research, immunohistochemistry, virtual microscopy and image analysis)

2007—*Biogen Idec, Cambridge, MA* (Distinguished Investigator) Announcement Pfizer Ann Arbor site to close dermatology therapeutic area to be shut down.

2007—Head Investigative Pathology (Specializing in immunohistochemistry methods, virtual microscopy and image analysis)

c. What was the impetus behind your career changes? Until I moved to pharma, my career changes (transitioning from diagnostician to researcher and moving to Texas A&M) grew from a desire to better understand dermatopathology. The more I did research, the better I liked doing it. I was offered the position at Pfizer because of my work in dermatopathology and dermatology research; however, as the job evolved, most of my work was

continued on page 19

continued from page 18

not associated with skin. At Biogen Idec, I was offered the position because of my experience in running a laboratory and experience with "molecular morphology." I now do very little dermatopathology or dermatology research. Although there are aspects of my "former life" that I miss, I like doing what I now do better that what I did before.

d. What did you take away from each position that was positive or negative?

1. Never expect a dysfunctional organization to get better over time.
2. If you want job security, stay with academia . . .
3. but you are more typecast in a position in academia than in industry. Industry offers many more opportunities to reinvent you.
4. Most biotechs are more academic than big pharmas because publications that are a way smaller firms use to gain credibility and to recruit/retain top scientists.
5. As a rule, biotechs are a better place to start a career in the pharmaceutical industry because they are smaller and you are forced to play many more roles in the drug discovery/development process.
6. Make yourself essential. As an individual, you have a much greater chance to succeed if you position yourself so that you do not do what you and most of your colleagues were hired to spend the greatest amount of their time doing (i.e., you seldom advance in academia by teaching the most courses and you seldom advance in industry by reading the most safety studies). I recognize that if everyone followed this advice there would be anarchy, but it still is a good rule to follow.
7. Large molecule development is much more creative and requires more morphologic evaluation in discovery but usually less morphologic evaluation in safety. Small molecule development requires less morphologic evaluation in discovery but greater morphologic evaluation in during safety.
8. All positions you hold should serve as stepping stones and you should learn from the good and bad aspects of each one.
9. Always make your boss look good. If you do not like your boss, still make your boss look good until he or she no longer supervises you or you leave.
10. There is life (and often a better one) after a site closure because sites close only if a company is struggling—never a good company to be with (see #1).

e. What advice do you have in making career path decisions? Taking a job with another organization (i.e., academia to industry, one company to another, industry to academia)

1. You can't always be logical. Logic will always favor staying put rather than taking a risk on a new position.
2. If you move from academia to industry, give it 18 months (most hate their first year in industry, I did).
3. Your kids will adapt much quicker to moving than you will (even if they are in high school).
4. Salary should be correlated with job satisfaction. Go for the position you will like the best, not the one that pays the most at the start. You will end up making much more in the long run in a job you like.
5. Always be looking for the next job. Even if you are totally content where you now are you should quietly try to interview once every 18–24 months. This is not so frequent as to make you look disgruntled, teaches you how competitive you are in the current market and it gives you a rare opportunity to see how other organizations function.
6. Change what you do in the same organization (i.e., moving from drug safety to discovery, from a toxicopathologist to a manager)
7. For most, it will be much easier to move to a new organization than to take a new career path where you now work
8. You either have to be "pretrained" for a new position in the same organization—most of those who believe they can self train on the job fail . . . or you need a mentor.

f. What were the your biggest misconceptions or ah-ha moments during career changes? The realization that you cannot do it alone. You need to be mentored. In my experience there are 2 types of mentors: 1) those who inspire you to "take the leap" to a career change and 2) those who teach you to be successful in your new role. Both are essential. In my experience, the inspirational mentor and the teaching mentor are seldom the same person. After thirty years working in academia and industry, I have largely made the transition from mentoree to mentor and have come to realize how important it is for a person going through a career change to be "mentorable." A mentor is under no obligation to train you. He/She has to enjoy the interaction. The best mentoring is "win-win" for the mentoree and the mentor. Below is a diagram of all who mentored me. Red are "inspirational mentors," blue are "teaching mentors," purple are individuals who served both functions. Although most who mentored me did so early in my career, later in my career as I made the transition from diagnostic dermatopathologist to researcher in dermatology, I was mentored by Dr. Patrick Venta and the transition from toxicopathologist to discovery investigator at Pfizer could not have occurred without the help of Dr. Mudher Albassam.



continued on page 20

Continued from page 19

Career Development Lunchtime Series—Jack R. Harkema, DVM, PhD

Current Position: University Distinguished Professor (Michigan State University)

Career Path: Government/Private Foundation ➔ Academia

Impetus for job change: Recruited by university (alma mater; college of veterinary medicine) to develop research and training program in toxicologic pathology; the right challenge for me; Good time in life to make the change (e.g., family factors); A good opportunity to teach and do independent research in a collaborative and collegial atmosphere; Could see myself contributing to the program; A good place to grow professionally and personally, while being of service to others.

Positive learning experiences from previous position: Research and administrative skills/experiences that were invaluable for becoming an independent academic researcher in my field of interest; Many opportunities were provided to me to grow in my area of expertise; No real negatives in previous position (it was hard to leave this job).

Advice: Don't go for the money; make decision on where you best fit and where you will be most happy in your day to day activities; Be honest with yourself and your colleagues; Develop a niche (expertise) early in your career; Always remember that our profession involves life-long learning; Go to a place that will give you good support, encouragement, respect, and space to grow and serve (e.g., good mentors, critical mass of co-workers; laboratory space; a defined mission/vision in which you can work); Look for opportunities to serve, rather than to be served.

Misconceptions: I will be less busy in academia compared to my current nonacademic position; I will have less research opportunities (sustainable collaborations and funding).

Career Development Lunchtime Series—Curtis A. Colleton, DVM, DACVP, PMP

Question A: What is your current Position?

Principal Pathologist, Drug Safety Evaluation.

Question B: What is your career path?

Military (Animal Disease Prevention and Control, Food Quality Assurance, Veterinary Pathology Board Certification, Medical Research Fellow, Research Pathologist/Primary Investigator) ➔ Private Practices (Diagnostic and Forensic Veterinary Pathology); (Veterinary Medicine and Surgery (Equine Medicine-Large Animal Hospital), (Mix Animal Medicine and Surgery Clinic) ➔ Small Business Entrepreneur (Restaurateur) ➔ CRO (Pharmaceutical and Environmental Toxicity Risk Assessment) ➔ Project Management (Project Management Certification) ➔ Pharmaceutical Research and Drug Safety Evaluation.

Question C: What was the impetus behind your career changes?

I was often impressed with the knowledge one received in a pursuit of board certification and had an innate belief that as a pathologist one should aspire to go where complacency was replaced with the ability to take calculated risks. As such, I always looked for opportunities to explore arenas either untouched or less taken. With this attitude/paradigm, I found myself looking at opportunities that other may consider risky or on the verge tipping the scale, so to speak. Albeit, all risk provides one with opportunities either for success or reevaluation of a less favorable course.

Question D: What did you take away from each position that was positive or negative?

This question dovetails nicely with the previous as to risk opportunities and the ability to build on success and all the more failures. Each position afforded me the opportunity to maximize my personal and career goals, that of being a loyal family head and provider and achieving the level of proficiency to compete in the biopharma arena. To this end, I used each position as building blocks and or stepping stones to this objective/goal. Building on successes and making positive readjustments in the face of miscalculations allow my family and me to appreciate all of the lessons learned and to implement corrective actions that prompted new job opportunities in this progressively complex, dynamic profession.

Question E: What advice do you have in making career path decisions?

Keep your eyes on the prize. What ever that prize is for you is an individual goal. I have come to know that if there is no prize, there is no desire and most likely, success in this field may not meet your anticipated expectations. Expectations postponed may be momentarily grievous, but persistence toward your prize and the zeal to obtain it shall promote the due diligence needed to negotiate the hurdles you will experience in your race for either financial, professional, and/or personal victories. The career path of choice should be one that allows for the sum accomplishment of all of these victories.

Question F: What were your biggest misconceptions or ah-ha moments during career changes?

I had to embrace and come to appreciate the reality of "Change" which in itself is not bad. Coupled with this fact was the "eureka" of understanding that in the face of change, there was a wonderful opportunity to seize success. Always looking, always searching, always thirsting for "new", unknowns and trying to better my ability for victories, I came to understand that life is a "sip" and in order to enjoy it you will need something to drink out of. Therefore, I came to know that one needed to always have a cup that was full of opportunities (positive relationships, directed professional preparation, first-in-class desire) to assure success in each career change.

STP MEMBERS PRESENT WORKSHOP IN CHINA

Society of Toxicologic Pathology members from Canada, China, France, and the United States gathered in Beijing on October 21, 2008 to present a 3-day continuing education workshop on Toxicologic Pathology to over 100 Chinese nationals. The workshop was organized by an STP subcommittee focused on promoting continuing education in China and included over 30 contact hours covering important topics on the toxicologic pathology of pharmaceuticals and biologic products. Topics presented included a discussion of pathology best practices and training, general patterns of toxicity, common background changes, rodent carcinogenesis bioassays, clinical pathology, and two days of lectures with digitized slide case reviews in cardiovascular and renal toxicologic pathology. All presentations were simultaneously translated into Chinese and attendees were provided with Chinese (Mandarin) translations of several STP Best Practices manuscripts, a DVD set of the digitized slide case studies, and a translated proceedings book containing all of the presentations. The attendees were very engaged and askedquestions covering a wide range of topics. Many stated that the conference was the best of its kind that they had attended. STP's Chinese partners for the workshop, Li Bo from the National Center for Safety Evaluation of Drugs (NCSED) and the National Institute for Control of Pharmaceutical and Biological Products (NICPBP), were outstanding and gracious hosts. Both the NCSED and NICPBP look forward to working with STP in advancing the science of toxicologic pathology in China.

From left to right: Dan Rudmann (Eli Lilly), Helen Han Hsu (J&J PRD), Monique Wells (Toxicology Pathology Services, Inc.), Deming Zhao, Jeff Engelhardt (Amgen Inc), Vince Meador (Amgen Inc), Jerry Ward, Bill Reagan (Pfizer), Nicole Hamelin (Charles River Laboratories), Kevin Donnelly (Covance Inc), Shan Shan Li, Xiantang Li (Pfizer), Judy Feng (Charles River Laboratories)

WHAT'S YOUR DIAGNOSIS?

This is one of the new cases submitted to the **"What's Your Diagnosis"** page of the STP Web site. To view more details about the case, followed by a link to the answer slides, select **"What's Your Diagnosis"** from the left menu list on the STP home page (**www.toxpath.org**). This case was submitted on 9/23.



Image provided by Drs. Bhanu Singh, Terry Blankenship, & Dave Malarkey, Cellular and Molecular Pathology Branch (BS, DM) Comparative Medicine Branch(TB), National Institute of Environmental Health Sciences

THE WRINKLED SECTION

Men, We Are in Good Hands

by James W. Crissman



Women know everything. This is just a fact I've come to accept, having been married to one for a very long time. Long ago, my starter wife knew a different set of everything, but everything none-the-less. The first thing that Jill, my permanent wife, knew that I did not was that our dog, Jellybean, had lost her tags. So when I lost Jellybean one evening a couple of weeks ago, I did not panic; I just stayed near the phone, believing it would ring soon and her rescuer would be on the other end. Of course it did not.

I had been doing some maintenance on our nearby mountain bike trails—a big dead pine had fallen across the trail and needed to be removed. Jellybean loves walking the trails with me, but she hates loud noises. Another thing my wife knew that I did not is that sound sensitive dogs get worse until they finally go deaf. Now at the heart of the story we have canine geriatric behavior science, a smart woman, and a beloved lost dog, so you know I'm in way over my head here.

When I fired up my chainsaw to cut the obstructing tree into manageable hunks, Jellybean bolted. We were a good hundred-fifty yards from the road, so I didn't worry. I should have. I made a few quick cuts and shut it down, then called her. She didn't come. I figured she was nearby, so I moved the logs. When she still didn't return, I went looking for her. Here I will mention that I am reasonably secure in my masculinity, but admit that I hoped my macho attire—brown Carhartts and hard hat—would compensate for my now slightly panicked yelling, "Jellybean! Jellybean, come!" Years ago I wanted to name her Butch, but the kids overruled. Personally, I would feel far more natural yelling, "Butch, git yer ass back here!" but Jellybean is her name, and a man should call things by their true name.

Jellybean

I could hear that it was rush hour on Eastman Road—a 60 mph concrete speedway—and I had been yelling for at least fifteen minutes. Finally I went to the road, afraid of what I might find. A man was bringing in his trash barrels on the other side. I ran across traffic and asked if he had seen a small Jack Russell Terrier.

"Yeah. About six cars almost hit her, then a blue van picked her up, turned around, and drove off," he said.

We called the pound, we made lost dog posters, we placed ads and sent mass e-mails. There were tears. There was a creep who said he was a trucker and he had her with him three states away and would buy a crate and ship her back if we would wire him cash. We Googled his phone number and got a fraud alert. A week later a call came from a man who gave only his first name, saying he saw the ad in the paper and thought a friend of his daughter might have her. He said he would check and call back. He did not call back and did not answer or return our calls—at least a dozen of them—for days.

We slowly realized this man was not a rescuer, but an absconder. He had called only to learn Jellybean's name. If he'd just decided to call her Butch he'd have gotten away with it. Jill was transformed into a hardnosed bottle-blond gumshoe sleuth on the trail of a dirtbag dognapper. She subscribed to an internet service that does reverse phone number lookup and found the guy's last name: Schwartzendruber. We still needed a street address, and no first and last names in the tri-city area phonebook matched, so she called every last Schwartzendruber in Midland, Bay City, and Saginaw. Surprisingly, there is a bunch. The last one was his ex-wife. And, as exes are predisposed to do, she ratted the dirtbag out. Jellybean is home. Women know everything.

EXHIBIT OPPORTUNITY AT 28TH ANNUAL MEETING IN WASHINGTON, D.C.

The Exhibitor Showcase at the 2009 STP Annual Meeting in Washington, D.C., offers an unmatched opportunity for vendors to reach a very targeted audience. More than 600 scientists and industry professionals come together to exchange ideas and present groundbreaking research findings in toxicologic pathology. The limited number of available booths guarantees that exhibitors will not get lost in a crowd of competitors.

To enhance the impact of the exhibits, the scientific poster sessions will be held in the exhibit hall, along with daily continental breakfasts and refreshment breaks. There will also be an Internet café in the exhibit hall where attendees can check e-mail during exhibit hours.

The Society values the support of exhibitors and believes the relationship between exhibiting companies and the STP membership is a mutually beneficial one. STP provides a wide array of benefits and services to exhibiting companies including two complimentary full conference registrations, company listing and booth location published in the Society's Annual Meeting *Program* guide, and more!

Please visit **www.toxpath.org** for more information, and make plans now to be a part of STP's 28th Annual Meeting, June 21–25, 2008, in Washington, D.C.

STUDENT SPEAKER AWARD WINNER SELECTED

Eric Schultze presents the STP Student Speaker Award to Dr. Angela Brice at the ACVP Annual Meeting in San Antonio, TX.

The third annual Society of Toxicologic Pathology (STP) Student Speaker Award competition was held in the Toxicologic Pathology Specialty Section at the concurrent meetings of the American College of Veterinary Pathologists (ACVP) and the American Society for Veterinary Clinical Pathology (ASVCP) in San Antonio on November 16, 2008. Dr. **Angela Brice** (Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD) was selected the winner for her presentation entitled, *"Minocycline Arrests CD4+ T Cells In The G0/G1 Phase Of The Cell Cycle And Increases The Activation Threshold."* [Abstract #211]. Dr. Brice received a $1,000 cash award to be used for lodging and travel to the 2009 STP meeting (Marriott Wardman Park Hotel in Washington, D.C.) and complimentary registration. Thanks are extended to our judges for the competition: **Drs. Brian Berridge** (GlaxoSmithKline), **Eric Blomme** (Abbott Laboratories), and **Eric Schultze** (Eli Lilly and Company). The fourth annual STP Student Speaker Award competition will be held at the concurrent meetings of the ACVP and ASVCP to be held at the Monterey Conference Center/Monterey Marriott Hotel in Monterey, California on December 5–9, 2009. Award application details can be found at **www.toxpath.org/student.asp**. We hope to see you there!

CALL FOR ACHIEVEMENT AWARD NOMINATIONS

Is there an STP Member you feel deserves to receive the **STP Achievement Award?**

This award is given by the Society of Toxicologic Pathology to a member in good standing who has played critical and influential roles in the area of toxicologic pathology over an extended period of time. Achievement may be demonstrated by a body of work in any or all of the following areas: scientific discovery, education, or regulatory standards.

Nomination Process

Nominators must be STP members. A nomination letter that highlights the candidate's achievement and influence in the area of toxicologic pathology and the candidate's CV are required and should be sent to **stp@toxpath.org** by March 1, 2008. Two supporting letters from other STP members are also required. Additional letters from non-STP members may be submitted. Nominations will be held forward for 2 years.

ACVP/STP COALITION BOARD NEWS

Tom Monticello Completes Term; Denzil Frost to Join Board

Tom Monticello

The Society wishes to thank Tom Monticello (Merck) for his outstanding service on the Board of Governors of the ACVP/STP Coalition for Veterinary Pathology Fellows. He has served for three years an STP representative. His term expires at the end of December.

Denzil Frost

Denzil Frost (Covance) has been selected by the STP Executive Committee to fill this open seat on the Board. He will join four other STP members currently serving: Pierre Tellier (Charles River Labs), Keith Harris (Wyeth), Susan Elmore (NIEHS), and Anne Ryan (Pfizer). ACVP has five representatives on the Board of Governors. For more information about the Coalition and its activities, visit **www.vetpathcoalition.org**.

WORKFORCE SURVEY RESULT

The report from the ACVP/STP/ASVCP 2007 workforce survey has just been posted on the STP Web site. There is link on the homepage at **www.toxpath.org.**

APPLY FOR A STUDENT TRAVEL AWARD!

Student Travel Awards are available to Graduate Students for participation in the Annual Symposium, of the Society of Toxicologic Pathology. Each of the ten students who are chosen will receive a $1,200 stipend to defray travel, and lodging costs associated with attending the convention, complimentary meeting registration, and complimentary student membership (for the following year). Recipients will be honored at an Awards Ceremony prior to the Annual Business Meeting on Wednesday. All recipients will be required to present a poster at the Symposium and several of the trainees will be asked to give an additional short oral presentation concurrent with scientific sessions.

Eligibility

To be eligible to compete for this award, trainees must be graduate students working in the field of experimental or toxicologic pathology or a related discipline (to include veterinary students, pathology residents [veterinary or medical] and/or MS or PhD students), and must be available to travel to Washington, D.C. to attend the meeting. Candidates who have recently completed (within 12 months of the application date) their graduate studies will also be eligible.

How to Apply

Return Student Travel applications (Items 1-4 below) by March 1, 2009 to:

STP Headquarters:
1821 Michael Faraday Drive,
Suite 300,
Reston, VA 20190

Phone: 703-438-7508
Fax: 703-438-3113

1. Complete the Travel Award Application on the **www.toxpath.org** Web site.
2. Ask your faculty advisor or a faculty member who is familiar with your work to submit a letter of nomination summarizing your qualifications.
3. Submit your *curriculum vitae*.
4. Include a statement of career goals in toxicologic pathology.
5. Submit an abstract on-line (should be limited to 250 words) describing your original work involving clinical or experimental research that relates to experimental or toxicologic pathology.

Submit Abstracts by March 1, 2009 on-line at www.toxpath.org

Washington, DC Attractions

continued from page 1

The White House on Pennsylvania Ave.

concealed in a button—bring to life the people and techniques behind some of the most influential espionage actions in world history.

Narrated tours are an ideal way to learn about the history and architecture and visit the many monuments and memorials in the city.

Most offer the option to visit sites as long as you would like, then board another tour bus to the next site. Links to tour operators are posted on the STP Web site and information is also available at the concierge desk at the Wardman Park Marriott.

Another popular way to see Washington, D.C. is by boat. Several cruise operators offer afternoon and evening tours on the Potomac. These are also posted on the Web site.

Popular sites just outside the city are Arlington National Cemetery in Virginia, just across the river in Virginia and Mount Vernon, and George Washington's home, which is also in Virginia. Virginia also has a growing number of wineries that are located a 60 to 90 minute drive from the city.

For more information about Washington, D.C., visit: **www.washington.org**

View of Jefferson Memorial from the Tidal Basin

UPCOMING MEETINGS

March 15–19, 2009
SOT 48th Annual Meeting
Baltimore, Maryland
http://www.toxicology.org/AI/MEET/AM2009/index.asp

June 20, 2009
NTP Symposium
Wardman Park Hotel
Washington, D.C.
www.toxpath.org/AM2009/index.asp

June 21–25, 2009
STP Annual Meeting
Wardman Park Hotel
Washington, D.C.
www.toxpath.org/AM2009/index.asp

July 21–25, 2009
8th Toxicology & Pathology in Drug Discovery & Development Short Course, Co-sponsored by the Society of Toxicologic Pathology.
Limited enrollment: To be placed on the waiting list and receive conference mailings, send a message to: E-mail: ope@cvm.uiuc.edu
University of Illinois at Urbana-Champaign
Champaign-Urbana, IL
www.cvm.uiuc.edu/ope/itp

November, 1–4, 2009
AMERICAN COLLEGE OF TOXICOLOGY 30TH ANNUAL MEETING
Wyndham Palm Springs, Palm Springs, CA.
For more information contact: 301-634-7840 or **www.actox.org**.

December 5–9, 2009
ACVP 2009
Monterey Conference Center and
the Monterey Marriott Hotel
Monterey, CA
www.acvp.org

June 19–24, 2010
29th STP Annual Symposium
Marriott Downtown Magnificent Mile
Chicago, IL

June 19–23, 2011
30th STP Annual Symposium
Hyatt Regency Denver
Denver, CO

June 24–28, 2012
31th STP Annual Symposium
Marriott Copley Place
Boston, MA